Model-Based Analysis of Costs and Outcomes of Non-Invasive Prenatal Testing for Down’s Syndrome Using Cell Free Fetal DNA in the UK National Health Service

摘要: Background Non-invasive prenatal testing (NIPT) for Down’s syndrome (DS) using cell free fetal DNA in maternal blood has the potential to dramatically alter way screening and diagnosis is delivered. Before NIPT can be implemented into routine practice, information required on its costs benefits. We investigated outcomes of DS as contingent first-line compared with current programme UK National Health Service. Methods We used a pre-existing model evaluate associated programme. The analysis was based hypothetical population 10,000 pregnant women. Model inputs were taken from published sources. main outcome measures number cases detected, procedure-related miscarriages total cost. Results At risk cut-off 1∶150 detects slightly fewer cases, miscarriages, same (around UK£280,000) at cost £500 per NIPT. As more expensive than £50 When uptake increases, small increase costs. Conclusions NIPT currently available private sector price £400-£900. If NHS lower end this range then would neutral or saving screening. likely produce favourable but greater cost. Further research needed under real world conditions.